A team of researchers from the Kobe University Graduate School of Medicine in Japan have developed a metabolomics-based approach to diagnose early-stage pancreatic cancer.1 The method uses gas chromatography coupled to mass spectrometry (GC?MS).
A team of researchers from the Kobe University Graduate School of Medicine in Japan have developed a metabolomics-based approach to diagnose early-stage pancreatic cancer.1 The method uses gas chromatography coupled to mass spectrometry (GC–MS).
Corresponding author Dr Masaru Yoshida commented: “Although surgical resection can be a curative treatment for pancreatic cancer, more than 80% of patients with pancreatic cancer have a locally advanced or metastatic tumour that is unresectable at the time of detection.” This is why scientists globally are trying to develop new methodsto detect the cancer in the earlier stages.
The team collected serum samples from 43 patients diagnosed with pancreatic cancer and 42 healthy volunteers. The analysis of the samples was challenging for the investigators. According to Yoshida, it was tough to measure several hundred metabolites in the serum samples at the same time with GC–MS.
The serum samples were compared from the two patient groups — in total, 159 metabolites were detected with 18 found to be significantly altered. The team developed and optimized the GC–MS method and selected four metabolites of interest to establish a diagnostic formula.
According to Yoshida, the novel diagnostic approach is safe and easy to apply. He told The Column that it is “expected to improve prognosis of patients diagnosed with pancreatic cancer by detecting their cancer early, when still in a resectable and curable state.”
Reference
1. T. Kobayashi et al, Cancer, Epidemiology, Biomarkers & Prevention,DOI:10.1158/1055-9965 (2013).
This story originally appeared in The Column. Click here to view that issue.
Separation Science Spotlight: What’s in Store for Chromatographers at Pittcon
February 25th 2025In this video interview, Emanuela Gionfriddo, Daniel Armstrong, and Nicholas Snow preview their talks at Pittcon, as well as give their opinions about what topics they hope to explore more at the conference.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.